XML 98 R11.htm IDEA: XBRL DOCUMENT v3.19.3
Revenue from contracts with customers
6 Months Ended 12 Months Ended
Jun. 30, 2019
Dec. 31, 2018
Revenue from Contract with Customer [Abstract]    
Revenue from contracts with customers

Note 4 – Revenue from contracts with customers

Disaggregated revenue

 

The Company provides diagnostic test products, laboratory services to hospitals, clinical laboratories and other healthcare provider customers, and enters into collaboration agreements with government agencies and healthcare providers. The revenues by type of service consist of the following:

 

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

 

2019

 

 

2018

 

 

2019

 

 

2018

 

Product sales

 

$

504,293

 

 

$

632,525

 

 

$

1,024,470

 

 

$

1,266,021

 

Laboratory services

 

 

5,250

 

 

 

1,100

 

 

 

5,250

 

 

 

9,790

 

Collaboration revenue

 

 

500,000

 

 

 

155,276

 

 

 

1,000,000

 

 

 

359,316

 

Total revenue

 

$

1,009,543

 

 

$

788,901

 

 

$

2,029,720

 

 

$

1,635,127

 

 

Deferred revenue

 

Changes in deferred revenue for the period were as follows:

 

Balance at December 31, 2018

 

 

 

 

 

 

 

$

15,824

 

Revenue recognized in the current period from the amounts in the beginning balance

 

 

 

 

 

 

 

 

(5,831

)

New deferrals, net of amounts recognized in the current period

 

 

 

 

 

 

 

 

 

Balance at June 30, 2019

 

 

 

 

 

 

 

$

9,993

 

 

Contract assets

 

The Company had no contract assets as of June 30, 2019, which are generated when contractual billing schedules differ from revenue recognition timing. Contract assets represent a conditional right to consideration for satisfied performance obligations that becomes a billed receivable when the conditions are satisfied.

 

Unsatisfied performance obligations

 

Remaining contract consideration for which revenue has not been recognized due to unsatisfied performance obligations was $575,000 at June 30, 2019, which the Company expects to recognize over the next six months.

Note 4 - Revenue from Contracts with Customers

Disaggregated Revenue

 

The Company provides diagnostic test products, laboratory services to hospitals, clinical laboratories and other healthcare provider customers, and enters into collaboration agreements with government agencies and healthcare providers. The revenues by type of service consist of the following:

 

 

 

December 31,

 

 

 

2018

 

 

2017

 

Product sales

 

$

2,395,626

 

 

$

2,771,869

 

Laboratory services

 

 

34,665

 

 

 

41,960

 

Collaboration revenue

 

 

516,016

 

 

 

397,178

 

Total revenue

 

$

2,946,307

 

 

$

3,211,007

 

Deferred Revenue

 

Changes in deferred revenue for the period were as follows:

 

Balance at December 31, 2017

 

 

 

$

24,442

 

Revenue recognized in the current period from the amounts in the beginning balance

 

 

 

 

(14,450

)

New deferrals, net of amounts recognized in the current period

 

 

 

 

5,832

 

Balance at December 31, 2018

 

 

 

$

15,824

 

Contract Assets

 

The Company had no contract assets as of December 31, 2018, which are generated when contractual billing schedules differ from revenue recognition timing. Contract assets represent a conditional right to consideration for satisfied performance obligations that becomes a billed receivable when the conditions are satisfied.

 

Unsatisfied Performance Obligations

 

The Company had no unsatisfied performance obligations related to its contracts with customers at December 31, 2018.